OncoResponse and Oregon Health & Science University Collaborate to Identify Novel Immuno-Oncology Targets
--Work conducted under the collaboration will provide insight into humoral response of elite responders to immunotherapy--
HOUSTON and PORTLAND, Ore. – Jan. 7, 2016 – OncoResponse, an immuno-oncology antibody discovery company, and the Knight Cancer Institute at Oregon Health & Science University today announced a collaboration to identify antibodies against novel targets in elite responders to cancer immunotherapy. The agreement provides OncoResponse with access to OHSU patient samples in two cancer indications, prostate cancer and chronic myeloid leukemia (CML), for immune repertoire screening to identify antibodies with exceptional reactivity from patients who have elite responses to cancer immunotherapies.
“By interrogating the humoral response of patients who have responded exceptionally well to immunotherapy, we can identify rare cancer-fighting antibodies and novel targets that may lead to the development of improved cancer treatments,” said Clifford J. Stocks, CEO of OncoResponse. “This collaboration will allow us access to invaluable patient sample sets that will undoubtedly be instrumental to the understanding of the immune response to cancer.”
Using a validated platform technology to rapidly screen antibodies made by the human immune system, OncoResponse scientists will identify those with exceptional reactivity and leverage this knowledge to identify potential targets for novel therapeutic development. Financial terms of the agreement were not disclosed.
“We are deeply committed to the development of improved cancer treatments for patients in need,” said Tomasz Beer, M.D., deputy director, OHSU Knight Cancer Institute. “This collaboration will provide valuable data that will allow us to develop a better understanding of what makes certain treatments successful and will inform the development of new therapies that have the potential to significantly impact patients’ lives.”
OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against novel immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded exceptionally well to cancer immunotherapies, OncoResponse has the potential to increase the success rate of these therapies across multiple cancer types. www.oncoresponse.com.
About Knight Cancer Institute at Oregon Health & Science University (OHSU)
The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute’s largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials. For additional information on the OHSU Knight Cancer Institute visit www.ohsu.edu/xd/health/services/cancer or follow us on Facebook and Twitter.